Mod GRF (1-29) & Ipamorelin Blend (10mg)

This 10mg blend combines Mod GRF (1-29) 5mg and Ipamorelin 5mg in a single vial, synthesized and lyophilized in the USA.

Each vial of Mod GRF (1-29) & Ipamorelin Blend (10mg) contains a pre-weighed ratio of Mod GRF (1-29) 5mg, Ipamorelin 5mg in a single lyophilized cake, simplifying multi-peptide research protocols.

Mod GRF (1-29) & Ipamorelin Blend (10mg) is studied within growth-hormone research for its influence on the somatotropic axis in experimental protocols.

Investigations of Mod GRF (1-29) & Ipamorelin Blend (10mg) commonly measure secretagogue activity and downstream signaling markers in controlled cell models.

Researchers pair Mod GRF (1-29) & Ipamorelin Blend (10mg) with pulse-profile analysis to characterize its release dynamics under standardized conditions.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Mod GRF (1-29) & Ipamorelin Blend (10mg). Summaries are provided for orientation only and reflect the cited sources.

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults^[1] — This clinical study evaluated how a single injection of CJC-1295, a long-acting analog of growth hormone-releasing hormone, affects GH and IGF-I secretion in healthy adults. The authors examined the duration and magnitude of the hormonal response to the modified GHRH peptide. The results suggested that CJC-1295 can produce sustained elevations of GH and IGF-I, supporting its characterization as a long-acting GHRH analog. (The Journal of Clinical Endocrinology & Metabolism 2006)

Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog^[2] — This study investigated whether continuous stimulation with the long-acting GHRH analog CJC-1295 preserves the natural pulsatile pattern of growth hormone secretion. Healthy men were studied during ongoing exposure to the peptide to assess both trough and peak GH dynamics. The findings indicated that GH pulsatility persists even under continuous GHRH analog stimulation, while baseline levels were elevated. (The Journal of Clinical Endocrinology & Metabolism 2006)

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats^[3] — This study tested whether the novel growth-hormone-releasing peptide ipamorelin can stimulate longitudinal bone growth in rats. The authors examined the peptide's effects on skeletal growth over the study period. The results suggested that ipamorelin promotes bone elongation, consistent with its GH-releasing activity. (Growth Hormone & IGF Research 1999)

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption^[4] — This pharmacokinetic study evaluated ipamorelin and other peptidyl growth hormone secretagogues, with particular attention to their absorption after nasal administration. The authors compared the pharmacokinetic profiles of these peptides to assess their suitability for non-invasive delivery. The findings indicated that nasal absorption characteristics vary among the secretagogues examined. (Xenobiotica 1999)

References

1. Teichman SL, et al.. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/3/799/10779632/jcem0799.p…
2. Ionescu M, Frohman LA. "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/12/4792/9059878/jcem4792.…
3. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Hormone & IGF Research. 1999. pubmed.ncbi.nlm.nih.gov/10373343/
4. Johansen PB, Hansen KT, Andersen JV, Johansen NL. "Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption." Xenobiotica. 1999. pubmed.ncbi.nlm.nih.gov/9879640/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.